A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease

Condition studied

Huntington’s Disease

Investigational medicinal product(s)

Eligibility

Primary endpoint

Change from baseline to Week 72 in cUHDRS.

Endpoint detail

Change from baseline to Week 72 in: − Total motor score (TMS) − Total functional capacity (TFC) − Independence scale (IS) − Stroop Color and Word test (SCWT) − Symbol digital modalities test (SDTM)